Amino Acid-Based Advanced Liquid Formulation Development for Highly Concentrated Therapeutic Antibodies Balances Physical and Chemical Stability and Low Viscosity.

To develop highly concentrated therapeutic antibodies enabling convenient subcutaneous application, well stabilizing pharmaceutical formulations with low viscosities are considered to be key. The purpose of this study is to select specific amino acid combinations that reduce and balance aggregation, fragmentation and chemical degradation, and also lower viscosity of highly concentrated liquid antibodies. As a model, the therapeutically well-established antibody trastuzumab (25->200 mg mL-1 ) in liquid formulation is used. Pre-testing of formulations based on a stabilizing and protecting solutions (SPS®) platform is conducted in a thermal unfolding model using differential scanning fluorimetry (DSF) and accelerated aging at 37 and 45 °C. Pre-selected amino acid combinations are further iteratively adjusted to obtain stable highly concentrated antibody formulations with low viscosity. Size exclusion chromatography (SE-HPLC) reveals significantly lower aggregation and fragmentation at specific amino acid:sugar and protein:excipient ratios. Dynamic viscosities <20 mPa * s of highly concentrated trastuzumab (≥200 mg mL-1 ) are measured by falling ball viscosimetry. Moreover, less chemical degradation is found by cationic exchange chromatography (CEX-HPLC) even after 6 months liquid storage at 25 °C. In conclusion, specifically tailored and advanced amino acid-based liquid formulations avoid aggregation and enable the development of stable and low viscous highly concentrated biopharmaceuticals.

[1]  Sandeep Kumar,et al.  Molecular basis of high viscosity in concentrated antibody solutions: Strategies for high concentration drug product development , 2016, mAbs.

[2]  Feng Qian,et al.  Viscosity-Lowering Effect of Amino Acids and Salts on Highly Concentrated Solutions of Two IgG1 Monoclonal Antibodies. , 2015, Molecular pharmaceutics.

[3]  Hanns‐Christian Mahler,et al.  Rheological characterization and injection forces of concentrated protein formulations: an alternative predictive model for non-Newtonian solutions. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[4]  E. Takai,et al.  Specific decrease in solution viscosity of antibodies by arginine for therapeutic formulations. , 2014, Molecular pharmaceutics.

[5]  J. Altrichter,et al.  Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates. , 2014, Vaccine.

[6]  C. Noe,et al.  Quality Control and Stability Studies with the Monoclonal Antibody, Trastuzumab: Application of 1D- vs. 2D-Gel Electrophoresis , 2014, International journal of molecular sciences.

[7]  K. Kemter.  Terminal Radiation Sterilization of Combination Products , 2014 .

[8]  Jindrich Cinatl,et al.  Nano-coating protects biofunctional materials , 2012 .

[9]  A. Lüking,et al.  A protein-stabilizing technology for enhanced antibody stability and antibody-binding profiles in a microchip array. , 2012, Biotechnology journal.

[10]  W. Xu,et al.  Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies , 2012, mAbs.

[11]  M. Mølhøj,et al.  Simultaneous Assessment of Asp Isomerization and Asn Deamidation in Recombinant Antibodies by LC-MS following Incubation at Elevated Temperatures , 2012, PloS one.

[12]  Jared S. Bee,et al.  Effects of surfaces and leachables on the stability of biopharmaceuticals. , 2011, Journal of pharmaceutical sciences.

[13]  Jan Jezek,et al.  Viscosity of concentrated therapeutic protein compositions. , 2011, Advanced drug delivery reviews.

[14]  N. Warne.  Development of high concentration protein biopharmaceuticals: the use of platform approaches in formulation development. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  L. Khawli,et al.  Charge variants in IgG1 , 2010, mAbs.

[16]  Aditya A Wakankar,et al.  Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. , 2010, Bioconjugate chemistry.

[17]  W. Friess,et al.  High‐Concentration Antibody Formulations , 2010 .

[18]  Steven J Shire,et al.  Formulation and manufacturability of biologics. , 2009, Current opinion in biotechnology.

[19]  Susanne Hostrup,et al.  Recent trends in stabilising peptides and proteins in pharmaceutical formulation – considerations in the choice of excipients , 2009, Expert opinion on drug delivery.

[20]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[21]  D. Ejima,et al.  Biotechnology applications of amino acids in protein purification and formulations , 2007, Amino Acids.

[22]  S. Shimizu,et al.  Preferential hydration and the exclusion of cosolvents from protein surfaces. , 2004, The Journal of chemical physics.

[23]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[24]  Bernhardt L Trout,et al.  Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. , 2011, Biotechnology journal.